Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

October 24, 2016

Study Completion Date

October 24, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Ga-68 labeled HBED-CC PSMA

The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.

DEVICE

Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)

Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective

DEVICE

Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)

Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.

Trial Locations (1)

94107

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Thomas Hope

OTHER

NCT02611882 - Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter